Giuseppe Caruso, MD
Pulmonary Disease · Bethpage, NYNPI 1750321840
Payments from drug & device makers
What this record shows
This record is dominated by education: $2,500 of the $3,945 with a category attached, or 63.4%. Intuitive Surgical accounts for 93.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $3,765 and has fallen 99.4% since, to $23 in 2025.
Across 22 payments — averaging $179.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- AbbVie$146
- Sanofi$46
- Boehringer Ingelheim$42
- Philips North America LLC$24
- AstraZeneca$15
What the payments were for
- Travel & lodging$1,09828%
- Food & beverage$3479%
- Education$2,50063%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $3,672 |
| AbbVie | 7 | $146 |
| Sanofi | 2 | $46 |
| Boehringer Ingelheim | 2 | $42 |
| Philips North America LLC | 1 | $24 |
| AstraZeneca | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,562
How this compares
$3,945 in reported general payments places this provider in the 70th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $51,981 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $10,521 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,662 |
| Arnuity ElliptaFluticasone Furoate | 15 | $4,037 |
| Roflumilast | 23 | $2,949 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 67 | $2,864 |
| Pantoprazole Sodium | 80 | $688 |
| Montelukast Sodium | 42 | $364 |
| Azithromycin | 50 | $325 |
| Prednisone | 94 | $226 |
| Methylprednisolone | 43 | $220 |
| Omeprazole | 29 | $181 |
| Doxycycline Hyclate | 24 | $169 |
| Famotidine | 14 | $76 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Bethpage
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
- Ali El AtatBrooklyn$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.